Multiple countries across Europe and parts of Asia suspended the use of AstraZeneca’s Covid-19 vaccine over fears the medication is leading to the development of blood clots in some patients who have received the medication.
AstraZeneca reported positive results from clinical trial programs for Brilinta and Farxiga, causing stock to jump 3.4 percent.
